Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-21 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Monday, July 21, 2026 | Edition 284

⚡ TL;DR

The Ebola Bundibugyo virus outbreak in DRC and Uganda has now reached 2,124 confirmed cases and 828 deaths as of July 15, making it the dominant global health emergency of 2026.

Mood: Elevated concern on two fronts — the Ebola PHEIC grinds forward while WHO simultaneously releases landmark dementia-prevention guidelines showing nearly half of all risk is modifiable.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (ACTIVE PHEIC)

  • As of July 15, 2026, WHO reports 2,124 confirmed cases and 828 confirmed deaths from Bundibugyo virus disease (BVD) in DRC, with cross-border transmission ongoing in Uganda. [1]
  • The WHO Director-General declared this outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, noting it does not yet meet criteria for a pandemic emergency. [2]
  • Africa CDC and WHO jointly launched a continental response plan on June 5, 2026, seeking to raise USD 518 million to support affected African countries. [3]
  • WHO issued its first comprehensive clinical management guidelines for filovirus disease, covering all Ebola types and Marburg, on June 17, 2026, directly in response to the BVD outbreak. [4]
  • The PARTNERS clinical trial opened patient enrolment in DRC on July 2, 2026, representing the first formal therapeutic trial specifically targeting Bundibugyo virus disease. [5]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, 2026, enabling rapid genetic detection in blood samples. [6]
  • CDC has activated enhanced Ebola airport screening at Washington-Dulles International Airport and Atlanta's Hartsfield-Jackson, both implemented in May 2026. [7] [8]
  • CDC issued its most recent statement on the DRC and Uganda Ebola outbreak on July 10, 2026. [9]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY, ONGOING)

  • As of the fifth WHO Disease Outbreak News report (July 2, 2026), the Andes hantavirus cluster linked to the M/V Hondius cruise ship continues with multiple confirmed cases across multiple countries. [10]
  • The outbreak was first reported to WHO on May 2, 2026, when seven cases (two confirmed, five suspected) were identified aboard the 147-person vessel.
  • CDC released its most recent hantavirus response transcript on June 24, 2026, indicating continued monitoring.

CYCLOSPORA — TACO BELL MULTISTATE OUTBREAK (ACTIVE, US)

  • CDC confirmed on July 17, 2026, that shredded iceberg lettuce served at Taco Bell locations is the source of Cyclospora infections across five states, with 1,644 people sickened.
  • CDC held a dedicated cyclosporiasis response briefing on July 14, 2026.

NIPAH VIRUS — INDIA (KERALA STATE)

  • WHO reported on June 25, 2026, that Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district; the adult male developed symptoms on May 30, 2026, and was hospitalized on June 10.
  • A prior NiV case was reported in Bangladesh (Rajshahi Division) in February 2026, involving fever and neurological symptoms confirmed by laboratory testing.

MPOX — RECOMBINANT STRAIN (GLOBAL WATCH)

  • WHO reported in February 2026 that two cases of a recombinant monkeypox virus strain containing genomic elements of both clade Ib and clade IIb MPXV have been documented globally.
  • Recombination is a known natural process occurring when two related viruses infect the same host simultaneously, per WHO.

YELLOW FEVER — AMERICAS (ONGOING TRANSMISSION)

  • From January 1 to May 26, 2026, six countries in the Americas and Africa reported 79 human infections, following elevated transmission activity that began in 2025 and persisted into 2026.

WEST NILE VIRUS — EARLY SEASON SIGNAL (US)

  • CDC warned on July 1, 2026, of a record early-season West Nile case count ahead of the July 4 holiday weekend, urging Americans to use mosquito repellent.

SALMONELLA AND FOODBORNE WATCH

  • Eleven people across 10 states are sick from the same Salmonella strain linked to frozen sprouted beans, per CDC alert dated July 17, 2026.

E. COLI — FROZEN BLUEBERRIES (US)

  • CDC posted a food safety alert on July 7, 2026, warning consumers not to eat recalled frozen blueberries linked to a multistate E. coli outbreak.

🧬 LONGEVITY & AGING

WHO DEMENTIA PREVENTION GUIDELINES — UP TO 45% OF RISK IS MODIFIABLE

  • WHO released updated guidelines on July 15, 2026, stating that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions across the life course.
  • The guidelines provide countries with specific recommendations targeting known modifiable risk factors for cognitive decline and dementia onset.

DELIRIUM AS A BRIDGE FROM SEVERE INFECTION TO DEMENTIA

  • Two independent Lancet Healthy Longevity commentaries (Sipila and Kivimaki; Penfold, Jiwaji, and MacLullich) propose that delirium following severe infection may be a mechanistic link accelerating subsequent dementia.
  • The hypothesis implies that treating delirium aggressively during acute infection episodes could reduce long-term cognitive decline risk.

NAD+ RESTORATION FOR AGED BONE REPAIR

  • A Europe PMC study (Jiang et al., Bioactive Materials) describes a senescent metabolism-modulating hierarchical scaffold that restores NAD+ homeostasis and redox balance specifically in aged bone tissue, improving repair outcomes.
  • NAD+ depletion is a hallmark of cellular senescence; restoring its levels is a leading target in geroscience research.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • Iorjiim et al. (Toxicology Reports, June 2026) found that kaempferol derived from Moringa oleifera increased lifespan and reversed efavirenz-induced functional senescence in Drosophila melanogaster.
  • The findings suggest kaempferol may counteract drug-induced aging phenotypes, though results remain preclinical in an insect model.

COLLAGEN XVII PROTECTS EPIDERMAL STEM CELLS FROM PHOTOAGING

  • Wang et al. (Annals of Medicine, July 16, 2026) showed that recombinant human collagen XVII shields epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway.
  • Epidermal stem cell loss is a key driver of skin aging; Notch pathway suppression is emerging as a candidate anti-photoaging target.

HYPERTENSION AND FRAILTY IN OLDER ADULTS — INDIA DATA

  • A letter published in Blood Pressure (July 7, 2026, Goyal et al.) highlights associations between hypertension and frailty among middle-aged and older adults drawing on the Longitudinal Ageing Study in India.
  • The data reinforce hypertension management as a dual longevity lever: cardiovascular risk reduction and frailty prevention.

DEMENTIA PREVENTION ERA — REAL-WORLD READINESS

  • Beeri and Gu writing in Lancet Healthy Longevity argue that preparing for a dementia prevention era requires accounting for socioeconomic, access, and equity constraints in the real world, not just biological targets.

WHO CANCER PROJECTIONS — A LONGEVITY THREAT QUANTIFIED

  • WHO reported on July 8, 2026, that new cancer cases are projected to nearly double by 2050, with 20.6 million new cases and close to 10 million deaths currently occurring annually.
  • The agency issued an urgent call to action for scaled-up prevention, screening, and treatment infrastructure globally.

💊 NEW CURES & APPROVALS

REVTORPYK (GEDATOLISIB) — CELCUITY INC.

  • Celcuity Inc. received an original FDA approval (NDA219908) for Revtorpyk, active ingredient gedatolisib, a PI3K/mTOR pathway inhibitor in oncology.

RETEVMO (SELPERCATINIB) — ELI LILLY AND CO.

  • Eli Lilly received two supplemental approvals (NDA213246 and NDA218160) for Retevmo (selpercatinib), a RET kinase inhibitor used in RET-altered non-small cell lung cancer, thyroid cancer, and other solid tumors.

ENLICITIDE — MERCK SHARP AND DOHME LLC

  • Merck Sharp and Dohme received an original FDA approval (NDA220848) for enlicitide chloride, a novel agent whose target is reflected in the application record.

REPATHA (EVOLOCUMAB) — AMGEN INC.

  • Amgen received a supplemental FDA approval (BLA125522) for Repatha (evolocumab), a PCSK9 inhibitor used to lower LDL cholesterol and reduce cardiovascular event risk.

AFATINIB DIMALEATE GENERICS

  • Hetero Labs Ltd V (ANDA210750) and Apotex (ANDA210725) each received original FDA approvals for generic afatinib dimaleate, an EGFR/HER2 kinase inhibitor used in non-small cell lung cancer.

NOTE: openFDA action dates are not timestamped; all approvals above reflect records active in the FDA database as surfaced in the current data window.

🧪 CLINICAL TRIALS

AMYLOID PET IMAGING — BALTIMORE LONGITUDINAL STUDY OF AGING (NCT07099053)

  • Researchers are using PET imaging to track amyloid protein accumulation in the aging brain longitudinally, aiming to identify early markers of cognitive decline in the Baltimore Longitudinal Study of Aging cohort; posted July 20, 2026.

PARTNERS TRIAL — BUNDIBUGYO VIRUS THERAPEUTICS (DRC, WHO-SPONSORED)

  • WHO announced on July 2, 2026, that the PARTNERS clinical trial opened enrolment in DRC, representing the first ever therapeutic evaluation trial for Ebola disease caused specifically by Bundibugyo virus. [5]

FITMI AD HOME THERAPY — MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE (NCT05504811)

  • This trial is evaluating a sensor-embedded home exercise device (FitMi AD) in individuals with mild cognitive impairment or mild Alzheimer's dementia, tracking direction and degree of movement; listed as active, updated July 20, 2026.

FOSTAMATINIB IN LUNG TRANSPLANT (SIMILAR TRIAL, NCT06948097)

  • The SIMILAR trial is evaluating fostamatinib, a Syk kinase inhibitor, for safety and tolerability in lung transplant patients with donor-specific antibodies, addressing a major cause of chronic allograft dysfunction; updated July 20, 2026.

DEC3-VEN VS. VENETOCLAX REGIMENS IN NEWLY DIAGNOSED AML (NCT07712848)

  • A prospective randomized multicenter trial is comparing 3-day decitabine plus venetoclax (DEC3-VEN) against two DA chemotherapy regimens in adult patients with newly diagnosed acute myeloid leukemia (AML), including those with KRAS and NRAS mutations; posted July 20, 2026.

BPL-1357 BROAD INFLUENZA VACCINE — H1N1 CHALLENGE STUDY (NCT07215858)

  • A controlled human infection challenge trial is testing BPL-1357, a broader influenza vaccine candidate, against H1N1 virus to assess pandemic preparedness utility; updated July 20, 2026.

📢 PUBLIC HEALTH

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center on June 12, 2026, to respond to the New World Screwworm (Cochliomyia hominivorax) threat, a parasitic fly larva that infects living tissue of mammals including humans.

GLOBAL CHILDHOOD IMMUNIZATION — 2025 DATA

  • WHO and UNICEF reported on July 15, 2026, that 90% of infants globally (approximately 116 million) received at least one DTP vaccine dose in 2025, and 85% (110 million) completed the full three-dose series.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador on July 13, 2026, as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of preventable blindness.

HEALTHCARE-ASSOCIATED INFECTIONS DECLINE IN US

  • CDC data released July 15, 2026, show a decline in hospital-acquired infections nationally in 2023, reflecting improved patient safety protocols across U.S. facilities.

US COMPLETES WHO WITHDRAWAL

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 failures, politicization, and a stated shift toward bilateral health agreements.

FIFA WORLD CUP 2026 PUBLIC HEALTH RESPONSE

  • CDC issued a statement on July 19, 2026, summarizing its public health readiness and response for the FIFA World Cup 2026, which brought 48 teams and millions of fans to 16 North American cities.

UNSAFE FOOD KILLS 1.5 MILLION ANNUALLY

  • WHO reported on June 3, 2026, that unsafe food causes 866 million illnesses and 1.5 million deaths per year globally, with children under age five facing nearly three times the illness risk of older individuals.

BIOMED PULSE is an informational briefing aggregating official public health and scientific sources. Nothing here is medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  3. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  4. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  5. Patient enrolment begins in a scientific trial to identify the… — WHO News
  6. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260721-02-v34 · 2026-07-21 02:01 UTC · pulse.uzylab.com

Read next